🔗 Visit the ClinicalTrials.gov page for NCT02061423
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. | Cancer Res | 2007 | 2.25 |
| 2 | HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. | Cancer | 2012 | 1.18 |
| 3 | A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. | J Immunother | 2012 | 1.02 |
| 4 | Development of vaccines for high-risk ductal carcinoma in situ of the breast. | Cancer Res | 2007 | 0.96 |
| 5 | Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer. | Breast Cancer Res | 2015 | 0.91 |
| 6 | Trial watch: Dendritic cell-based anticancer therapy. | Oncoimmunology | 2014 | 0.90 |